Posted by Michael Wonder on 04 Feb 2020
Anavex Life Sciences announces fast track designation granted by U.S. FDA for Anavex 2-73 (blarcamesine) clinical development program for the treatment of Rett syndrome
3 February 2020 - Anavex Life Sciences today announced that the U.S. FDA has granted fast track designation for Anavex 2-73 (blarcamesine) clinical development program for the treatment of Rett syndrome.
In the U.S. Phase 2 Rett syndrome study to date, Anavex 2-73 (blarcamesine) demonstrated significant improvements of the two global efficacy endpoints, the Rett Syndrome Behaviour Questionnaire total score and the Clinical Global Impression – Improvement.
